RU2767445C2 - Способы лечения сердечной недостаточности и ишемического-реперфузионного повреждения сердца - Google Patents

Способы лечения сердечной недостаточности и ишемического-реперфузионного повреждения сердца Download PDF

Info

Publication number
RU2767445C2
RU2767445C2 RU2019119110A RU2019119110A RU2767445C2 RU 2767445 C2 RU2767445 C2 RU 2767445C2 RU 2019119110 A RU2019119110 A RU 2019119110A RU 2019119110 A RU2019119110 A RU 2019119110A RU 2767445 C2 RU2767445 C2 RU 2767445C2
Authority
RU
Russia
Prior art keywords
shock wave
heart
heart failure
inhibitor
wave therapy
Prior art date
Application number
RU2019119110A
Other languages
English (en)
Russian (ru)
Other versions
RU2019119110A (ru
RU2019119110A3 (cg-RX-API-DMAC7.html
Inventor
Саломон НАРОДДЕН
Original Assignee
Саломон НАРОДДЕН
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Саломон НАРОДДЕН filed Critical Саломон НАРОДДЕН
Publication of RU2019119110A publication Critical patent/RU2019119110A/ru
Publication of RU2019119110A3 publication Critical patent/RU2019119110A3/ru
Application granted granted Critical
Publication of RU2767445C2 publication Critical patent/RU2767445C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/22—Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for
    • A61B17/225—Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for for extracorporeal shock wave lithotripsy [ESWL], e.g. by using ultrasonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
    • C12Y304/14005—Dipeptidyl-peptidase IV (3.4.14.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medical Informatics (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
RU2019119110A 2016-11-24 2017-11-17 Способы лечения сердечной недостаточности и ишемического-реперфузионного повреждения сердца RU2767445C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1619861.6A GB201619861D0 (en) 2016-11-24 2016-11-24 Treatments for heart failure and cardiac ischaemic reperfusion injury
GB1619861.6 2016-11-24
PCT/GB2017/053473 WO2018096319A1 (en) 2016-11-24 2017-11-17 Treatments for heart failure and cardiac ischaemic reperfusion injury

Publications (3)

Publication Number Publication Date
RU2019119110A RU2019119110A (ru) 2020-12-24
RU2019119110A3 RU2019119110A3 (cg-RX-API-DMAC7.html) 2021-08-30
RU2767445C2 true RU2767445C2 (ru) 2022-03-17

Family

ID=58073526

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019119110A RU2767445C2 (ru) 2016-11-24 2017-11-17 Способы лечения сердечной недостаточности и ишемического-реперфузионного повреждения сердца

Country Status (16)

Country Link
US (1) US20190374623A1 (cg-RX-API-DMAC7.html)
EP (1) EP3544624B1 (cg-RX-API-DMAC7.html)
JP (1) JP7231543B2 (cg-RX-API-DMAC7.html)
KR (1) KR102678011B1 (cg-RX-API-DMAC7.html)
CN (1) CN109996558A (cg-RX-API-DMAC7.html)
AU (1) AU2017365926B2 (cg-RX-API-DMAC7.html)
CA (1) CA3044624A1 (cg-RX-API-DMAC7.html)
ES (1) ES3017482T3 (cg-RX-API-DMAC7.html)
GB (1) GB201619861D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20250664T1 (cg-RX-API-DMAC7.html)
HU (1) HUE071244T2 (cg-RX-API-DMAC7.html)
MY (1) MY200960A (cg-RX-API-DMAC7.html)
PL (1) PL3544624T3 (cg-RX-API-DMAC7.html)
RS (1) RS66778B9 (cg-RX-API-DMAC7.html)
RU (1) RU2767445C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018096319A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2818731C1 (ru) * 2023-12-25 2024-05-03 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" Способ лечения начальных проявлений сердечной недостаточности низкоинтенсивным магнитолазерным излучением

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023281447A1 (en) * 2021-07-07 2023-01-12 Radius Health, Inc. Methods of treating a cardiovascular ischemic event
US20240122794A1 (en) * 2022-10-12 2024-04-18 Softwave Tissue Regeneration Technologies, Inc. Acoustic shock wave or pressure pulse treatment and methods of use for anti-aging
CN115998768B (zh) * 2023-02-07 2024-01-30 西南医科大学 M2型巨噬细胞外泌体在制备治疗心肌缺血再灌注损伤药物中的应用
CN117257785A (zh) * 2023-11-09 2023-12-22 新疆医科大学 没食子酸及其衍生物在制备预防和/或治疗心肌损伤药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007118680A2 (en) * 2006-04-19 2007-10-25 Ludwig-Maximilians-Universität München Remedies for ischemia
US8455435B2 (en) 2006-04-19 2013-06-04 Ludwig-Maximilians-Universitat Munchen Remedies for ischemia
KR20110135411A (ko) * 2009-03-27 2011-12-16 브리스톨-마이어스 스큅 컴퍼니 Dpp-iv 억제제로 주요 유해 심장혈관 이벤트를 예방하는 방법
US9526728B2 (en) * 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Ayako Takahashi et al., Dipeptidyl-peptidase IV inhibition improves pathophysiology of heart failure and increases survival rate in pressure-overloaded mice, Am J Physiol Heart Circ Physiol, 2013, Vol.304, pp. H1361-H1369. *
Sarah Chua et al., Inhibition of dipeptidyl peptidase-IV enzyme activity protects against myocardial ischemia-reperfusion injury in rats / Journal of Translational Medicine, 2014, Vol. 12, pp.1-18. *
Sarah Chua et al., Inhibition of dipeptidyl peptidase-IV enzyme activity protects against myocardial ischemia-reperfusion injury in rats / Journal of Translational Medicine, 2014, Vol. 12, pp.1-18. Yoshitaka Ito et al., Cardiac shock wave therapy ameliorates left ventricular remodeling after myocardial ischemia-reperfusion injury in pigs in vivo/ Coronary artery disease, 2010, Vol.21, N.5, pp.304-11. Ю.А. Васюк и др., Эффективность ударно-волновой терапии в лечении хронической сердечной недостаточности ишемического генеза / Кардиология, 2010, Vol.12, pp.22-26. Ayako Takahashi et al., Dipeptidyl-peptidase IV inhibition improves pathophysiology of heart failure and increases survival rate in pressure-overloaded mice, Am J Physiol Heart Circ Physiol, 2013, Vol.304, pp. H1361-H1369. *
Yoshitaka Ito et al., Cardiac shock wave therapy ameliorates left ventricular remodeling after myocardial ischemia-reperfusion injury in pigs in vivo/ Coronary artery disease, 2010, Vol.21, N.5, pp.304-11. *
Ю.А. Васюк и др., Эффективность ударно-волновой терапии в лечении хронической сердечной недостаточности ишемического генеза / Кардиология, 2010, Vol.12, pp.22-26. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2818731C1 (ru) * 2023-12-25 2024-05-03 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" Способ лечения начальных проявлений сердечной недостаточности низкоинтенсивным магнитолазерным излучением

Also Published As

Publication number Publication date
KR20190100199A (ko) 2019-08-28
PL3544624T4 (pl) 2025-11-03
US20190374623A1 (en) 2019-12-12
WO2018096319A1 (en) 2018-05-31
RU2019119110A (ru) 2020-12-24
EP3544624C0 (en) 2025-02-12
RU2019119110A3 (cg-RX-API-DMAC7.html) 2021-08-30
GB201619861D0 (en) 2017-01-11
CA3044624A1 (en) 2018-05-31
KR102678011B1 (ko) 2024-06-25
JP7231543B2 (ja) 2023-03-01
EP3544624B1 (en) 2025-02-12
HUE071244T2 (hu) 2025-07-28
EP3544624A1 (en) 2019-10-02
CN109996558A (zh) 2019-07-09
HRP20250664T1 (hr) 2025-10-24
RS66778B9 (sr) 2025-08-29
MY200960A (en) 2024-01-26
PL3544624T3 (pl) 2025-11-03
JP2020510616A (ja) 2020-04-09
AU2017365926A1 (en) 2019-07-04
ES3017482T3 (en) 2025-05-13
AU2017365926B2 (en) 2025-06-05
RS66778B1 (sr) 2025-06-30

Similar Documents

Publication Publication Date Title
Ohnishi et al. Transplantation of mesenchymal stem cells attenuates myocardial injury and dysfunction in a rat model of acute myocarditis
US10583103B2 (en) Method of treating heart failure with preserved ejection fraction with probenecid
US20090297470A1 (en) Remedies for ischemia
EP3544624B1 (en) Treatments for heart failure and cardiac ischaemic reperfusion injury
Li et al. Treatment with granulocyte colony-stimulating factor ameliorates chronic heart failure
KR20220147712A (ko) 심혈관 병태에서의 세마글루타이드
ES2848348T3 (es) Composiciones y métodos de tratamiento con ifetroban de la fibrosis cardíaca
Rajani et al. Post-infarct morphine treatment mitigates left ventricular remodeling and dysfunction in a rat model of ischemia-reperfusion
Toh et al. Transplantation of cardiotrophin-1–expressing myoblasts to the left ventricular wall alleviates the transition from compensatory hypertrophy to congestive heart failure in Dahl salt-sensitive hypertensive rats
JP2019507174A (ja) 心血管疾患におけるリラグルチド
Sung et al. Obesity and preclinical changes of cardiac geometry and function
US20240139207A1 (en) Methods for treating pulmonary hypertension
Axelgaard et al. Effects of chronic treprostinil treatment on experimental right heart hypertrophy and failure
US20220387408A1 (en) Use of mast cell stabilizer for the treatment of heart failure with preserved ejection fraction
Kawaguchi et al. The effect of telmisartan on the ventricular systolic function in dogs with experimental supraventricular tachyarrhythmia
Ripa et al. Safety of Bone Marrow Stem Cell Mobilization Induced by Granulocyte-Colony Stimulating Factor: 30 Days’ Blinded Clinical Results from the Stem Cells in Myocardial Infarction (STEMMI) Trial
JP2018502055A (ja) マクロファージ炎症性タンパク質−1β抑制剤の使用方法
Alkhunaizi et al. Mechano-Ino-Chronotropic Unloading in Cardiogenic Shock Due to Acute Myocardial Infarction—Hemodynamic Insights From Simulation Modeling
Tanaka et al. Clenbuterol plus granulocyte colony-stimulating factor regulates stem/progenitor cell mobilization and exerts beneficial effect by increasing neovascularization in rats with heart failure
Shikraki et al. PS-B03-4: A NOVEL SOLUBLE EPOXIDE HYDROLASE VACCINE PROTECTS MURINE CARDIAC MUSCLE AGAINST MYOCARDIAL INFARCTION
Dulsat European Society of Cardiology (ESC) Congress 2019. Paris, France-August 31-September 4, 2019
HK40101211A (en) Pharmaceutical composition for preventing or treating systemic sclerosis
Polhemus et al. Polhemus. BRC. Repeated cell transplan denervation. 2019. pdf
Pastormerlo et al. P4025 Sympathetic renal denervation after acute myocardial infarction results in increased myocardial salvage in pigs
Scarlini et al. Effects of cholecalciferol supplementation in patients with low vitamin D levels and chronic heart failure-a randomized double blind controlled trial